Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,363 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,720 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,404)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04862260 | Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma | active not recruiting | Early Phase 1 | 3 | CHU de Quebec-Universite LavalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04298606 | A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence | completed | Early Phase 1 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07164027 | Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial | recruiting | Early Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07274813 | A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors | recruiting | Early Phase 1 | 254 | Shanghai Henlius BiotechINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03164486 | First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide | active not recruiting | Early Phase 1 | 27 | Julie L. Sutcliffe, Ph.DOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06511037 | PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis | recruiting | Early Phase 1 | 10 | University of California, IrvineOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06305962 | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors | recruiting | Early Phase 1 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07235280 | Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma | recruiting | Early Phase 1 | 48 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT01858025 | Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma | completed | Early Phase 1 | 25 | Massachusetts General HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05683964 | Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | active not recruiting | Early Phase 1 | 9 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05160597 | Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy | active not recruiting | Early Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05493566 | Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer | recruiting | Early Phase 1 | 15 | Emory UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03543969 | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | active not recruiting | Early Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05620342 | Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer | recruiting | Early Phase 1 | 24 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04457089 | Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer | completed | Early Phase 1 | 18 | Marc GoodmanOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06639191 | [177Lu]Lu-AKIR001 First-in-human Study(AKIR001) | recruiting | Early Phase 1 | 15 | Karolinska University HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05553782 | Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers | recruiting | Early Phase 1 | 30 | Brigham and Women's HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07356466 | Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma(FUGES032) | enrolling by invitation | Early Phase 1 | 100 | Fujian Medical UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07352345 | Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 150 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06220214 | Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer | recruiting | Early Phase 1 | 30 | Alison StopeckOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07340424 | A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer. | recruiting | Early Phase 1 | 15 | Xiaorong SunOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07341360 | Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei(Pseudovax) | recruiting | Early Phase 1 | 10 | Oslo University HospitalOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07316361 | GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer(GYNORYLAQ™) | enrolling by invitation | Early Phase 1 | 40 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05336266 | A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma(KetoROCX) | active not recruiting | Early Phase 1 | 28 | Andrew Hendifar, MDOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05183048 | Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma | recruiting | Early Phase 1 | 14 | University of Alabama at BirminghamOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07285434 | Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer(Microlyvaq™) | enrolling by invitation | Early Phase 1 | 90 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05845307 | Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck | withdrawn | Early Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT03511196 | Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | active not recruiting | Early Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07246304 | TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC | recruiting | Early Phase 1 | 24 | TCRCure Biopharma Ltd.INDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06190197 | Prophylactic Antibiotics in Cystectomy With Diversion | recruiting | Early Phase 1 | 120 | University of MinnesotaOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06008275 | Neratinib in Combination With Ruxolitinib in Patients With mTNBC | recruiting | Early Phase 1 | 20 | Baylor Research InstituteOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03734653 | Testosterone Therapy in Castration Resistant Prostate Cancer | completed | Early Phase 1 | 30 | University of Colorado, DenverOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT02111941 | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Early Phase 1 | 19 | Mayo ClinicOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT06914999 | Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer | recruiting | Early Phase 1 | 20 | Emory UniversityOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04049227 | Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer | completed | Early Phase 1 | 27 | Northwestern UniversityOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT04712721 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. | terminated | Early Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 10, 2025 | clinicaltrials |
| NCT05603559 | 177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer | recruiting | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06664151 | A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision | recruiting | Early Phase 1 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04857684 | SBRT + Atezolizumab + Bevacizumab in Resectable HCC | active not recruiting | Early Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07201064 | A Study of SZ1003 Injection in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 12 | Guangdong ProCapZoom Biosciences Co., Ltd.INDUSTRY | 0 | Oct 1, 2025 | clinicaltrials |
| NCT02467738 | Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer | completed | Early Phase 1 | 30 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT03039413 | Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy | completed | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05105087 | Gynecological Sentinel Lymph Nodes CEUS | completed | Early Phase 1 | 9 | Thomas Jefferson UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06273852 | A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors | completed | Early Phase 1 | 8 | Pure Biologics S.A.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06700070 | A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors | recruiting | Early Phase 1 | 12 | Pure Biologics S.A.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07113977 | Clinical Study of a Novel Humanized CD70-Targeted CAR-T Cell Incorporating TLR2 for Advanced Renal Cell Carcinoma Therapy | not yet recruiting | Early Phase 1 | 30 | Wei GuanOTHER | 0 | Aug 11, 2025 | clinicaltrials |
| NCT06246786 | Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer) | withdrawn | Early Phase 1 | 0 | Virginia G. KaklamaniOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06086925 | A Window of Opportunity Study of Black Raspberry for Patients With HNSCC | withdrawn | Early Phase 1 | 0 | Mitchell MachtayOTHER | 0 | Jul 11, 2025 | clinicaltrials |
| NCT05557708 | A Safety Study of 212Pb-Pentixather Radioligand Therapy | not yet recruiting | Early Phase 1 | 20 | Yusuf MendaOTHER | 1 | Jul 8, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Mar 19, 2026source: clinicaltrials